Abstract
Background Curcumin, the most active component in turmeric helps attenuate DOMS.
Objectives A clinical study was conducted to evaluate efficacy and safety of AQUATURM® in subjects with Delayed Onset Muscle Soreness (DOMS).
Methods Twenty healthy men in each of the two subsets completed the study. Subjects were assigned as per a computer-generated randomization list. In subset-I, subjects were asked to take given product in a dose of 1 capsule (250 mg) for 2 days. In subset-II, subjects were asked to take given product in a dose of 1 capsule (250mg) for 5 days. In subset-I, eccentric exercise was performed at hour 6. In subset-II eccentric exercise was performed at day 2.5. The outcome measures were muscle pain, tenderness, swelling, jump performance, muscle inflammatory markers, rescue medication and adverse events. These outcome measures were evaluated at 0 hour, at 6 hours (immediately after exercise), at 24 hours and at 48 hours in subset-I, and at day 1, day 2.5 baseline (immediately after exercise), at 24 hours from baseline and at 48 hours from baseline in subset-II.
Results A significant reduction in muscle pain, tenderness and swelling post eccentric exercise was observed in AQUATURM® Capsule group compared to placebo group in both the subsets of the study. Additionally, when compared to the placebo group, the AQUATURM® group showed a statistically significant increase in post exercise average single-leg vertical squat jump. AQUATURM® Capsule was well tolerated by the subjects.
Conclusion Supplementation of AQUATURM® Capsule prior to and following heavy eccentric exercise in healthy men resulted in relieving muscle pain, tenderness and swelling from DOMS.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2021/08/035419, Registered on: 04/08/2021
Funding Statement
Lodaat Pharma, USA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Committee KVTR Ayurveda College and Hospital, Boradi, Dhule District, India.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
